scholarly journals Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy

2013 ◽  
Vol 20 (4) ◽  
pp. 222-228 ◽  
Author(s):  
E R Camp ◽  
C Wang ◽  
E C Little ◽  
P M Watson ◽  
K F Pirollo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Transferrin Receptor ◽  
P53 Gene ◽  
Wild Type ◽  
Receptor Targeting ◽  
Wild Type P53

scholarly journals Transferrin Receptor Targeting Nanomedicine Delivering Wild Type P53 Gene Sensitizes Pancreatic Cancer to Gemcitabine Therapy

2013 ◽  
Vol 179 (2) ◽  
pp. 242-243
Author(s):  
E.R. Camp ◽  
C. Wang ◽  
P. Watson ◽  
E. Little ◽  
K.F. Pirollo ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Transferrin Receptor ◽  
P53 Gene ◽  
Wild Type ◽  
Receptor Targeting ◽  
Wild Type P53

scholarly journals Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer

2000 ◽  
Vol 7 (4) ◽  
pp. 545-556 ◽  
Author(s):  
Manel Cascalló ◽  
Joaquim Calbó ◽  
Josef Lluís Gelpí ◽  
Adela Mazo
Keyword(s):  
Pancreatic Cancer ◽  
P53 Gene ◽  
Human Pancreatic Cancer ◽  
Wild Type ◽  
Wild Type P53

Abstract 4852: Boosting immunity against pancreatic cancer by OBP-702 (Pfifteloxin), telomerase-specific replicative adenovirus armed with wild-type p53 gene

2019 ◽  
Author(s):  
Hiroyuki Araki ◽  
Hiroshi Tazawa ◽  
Takuro Fushimi ◽  
Takeyoshi Nishiyama ◽  
Satotu Kikuchi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
P53 Gene ◽  
Wild Type ◽  
Wild Type P53

Abstract 4852: Boosting immunity against pancreatic cancer by OBP-702 (Pfifteloxin), telomerase-specific replicative adenovirus armed with wild-type p53 gene

2019 ◽  
Author(s):  
Hiroyuki Araki ◽  
Hiroshi Tazawa ◽  
Takuro Fushimi ◽  
Takeyoshi Nishiyama ◽  
Satotu Kikuchi ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
P53 Gene ◽  
Wild Type ◽  
Wild Type P53

scholarly journals Tumor Eradication by Wild-type p53-specific Cytotoxic T Lymphocytes

1997 ◽  
Vol 186 (5) ◽  
pp. 695-704 ◽  
Author(s):  
Michel P.M. Vierboom ◽  
Hans W. Nijman ◽  
Rienk Offringa ◽  
Ellen I.H. van der Voort ◽  
Thorbald van Hall ◽  
...  
Keyword(s):  
T Lymphocytes ◽  
Tumor Cells ◽  
Cytotoxic T Lymphocytes ◽  
Normal Tissue ◽  
P53 Protein ◽  
P53 Gene ◽  
Wild Type ◽  
Wild Type P53 ◽  
Tumor Outgrowth ◽  
Tumor Eradication

The tumor suppressor protein p53 is overexpressed in close to 50% of all human malignancies. The p53 protein is therefore an attractive target for immunotherapy. Cytotoxic T lymphocytes (CTLs) recognizing a murine wild-type p53 peptide, presented by the major histocompatibility complex class I molecule H-2Kb, were generated by immunizing p53 gene deficient (p53 −/−) C57BL/6 mice with syngeneic p53-overexpressing tumor cells. Adoptive transfer of these CTLs into tumor-bearing p53 +/+ nude mice caused complete and permanent tumor eradication. Importantly, this occurred in the absence of any demonstrable damage to normal tissue. When transferred into p53 +/+ immunocompetent C57BL/6 mice, the CTLs persisted for weeks in the absence of immunopathology and were capable of preventing tumor outgrowth. Wild-type p53-specific CTLs can apparently discriminate between p53-overexpressing tumor cells and normal tissue, indicating that widely expressed autologous molecules such as p53 can serve as a target for CTL-mediated immunotherapy of tumors.

Wild-type p53 gene transfection in human cultured sarcomas: Effect of CDDP

2001 ◽  
Author(s):  
Koji Endo ◽  
Itaru Kuratate ◽  
Mari Watanabe ◽  
Haruhiko Yoshida ◽  
Ryota Teshima ◽  
...  
Keyword(s):  
Gene Transfection ◽  
P53 Gene ◽  
Wild Type ◽  
Wild Type P53
Sign in / Sign up

Export Citation Format

Share Document